Please wait…

28/08/2018 15:35:24
A A | Print

Brandenburg: CDU regt Entschädigungsfonds für Opfer des Pharma-Skandals an


POTSDAM (dpa-AFX) - Die CDU-Fraktion im Brandenburger Landtag hat einen Entschädigungsfonds für die Opfer des Medikamenten-Skandals angeregt. Nach dem Bericht der Expertenkommission habe es gravierende Mängel in der Arzneimittelaufsicht des Landes gegeben, sagte Fraktionschef Ingo Senftleben am Dienstag. "Wir sehen die moralische Notwendigkeit, gegenüber den betroffenen Patienten Verantwortung zu übernehmen", sagte Senftleben. "Es wäre schön, wenn der Landtag dafür geschlossen ein Signal geben könnte." Laut dem Bericht hätten die Behörden spätestens im Februar 2017 wegen konkreten Hinweisen auf Handel mit gestohlenen Krebsmedikamenten eingreifen müssen.

Wichtigste Aufgabe sei es, zunächst die Patienten zu identifizieren, die möglicherweise unsachgemäß gelagerte Medikamente bekommen haben, sagte Senftleben. "Bei uns haben sich schon einige Betroffene gemeldet." Nach Angaben der Behörden waren die Medikamente in mindestens fünf Bundesländer geliefert worden. Unklar ist weiter, wie viele Patienten insgesamt die Medikamente bekamen und ob diese weniger wirksam waren./kp/DP/tos

Fund finder

Fund name:
Investment Company:
Fund type:
 
Initial Fee:
Minimum age:
Currencies:
Performance one Year:
Volume:
Sort by:
pagehit

The following Disclaimer and Information has been prepared by Voltabox AG (the “Issuer”) for the purpose of publishing THE securities prospectus by the issuer. Deutsche Boerse AG does not assume any responsibility for the content of the issuer`s Disclaimer and information.

 

Important Information


 

The information contained on the following web pages is directed only at persons who are resident of or domiciled in the Federal Republic of Germany (“Germany”) or the Grand Duchy of Luxembourg (“Luxembourg”). The following information does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities. No offer of securities of the Issuer is being, or will be, made to the public outside Germany and Luxembourg. The offer in Germany and Luxembourg is being made solely on the basis of the securities prospectus (including any amendments thereto) which has been approved by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and which has been published on the Issuer’s website. Any investment decision regarding the publicly offered securities of the Issuer should only be made on the basis of the securities prospectus. The securities prospectus is available free of charge from the Issuer (Artegastraße 1, 33129 Delbrück, Germany; Tel.: +49 (0)5250 9930-900; Fax: +49 (0)5250 9762-102) and on the Issuer’s website (www.voltabox.ag).



The information contained on the following web pages is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States of America (“United States”), Canada, Australia or Japan. The Issuer’s shares, and the securities offered in the course of the offer, have not been and will not be registered under the US Securities Act of 1933, as amended (“Securities Act”), or with any other securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold or delivered within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Issuer does not intend to register the offer or parts thereof in the United States or make an offer to the public in the United States, Canada, Australia or Japan.



The information contained on the following web pages is not for distribution to persons who are located in the United States, Canada, Australia or Japan or any other jurisdiction where the offer of the securities to the public is not taking place. Any violation of these restrictions may constitute a breach of the securities laws of these countries. The copying, forwarding or other transmission of the content of the following web pages is prohibited.

By clicking the "I AGREE" button below, you warrant that (i) you have read and accepted the foregoing information and restrictions in full and (ii) you are a resident of or domiciled in Germany or Luxembourg, and (iii) you agree not to distribute or forward the information contained on the following web pages to any person who is not a resident of or domiciled in Germany or Luxembourg.

 


We regret that, due to regulatory restrictions, we are unable to provide you with access to the following web pages.